Stage IIIb non-small cell lung cancer
Conditions
Interventions
case series:Albumin paclitaxel 200mg/m2 + nedaplatin 70mg/m2, bronchial artery perfusion, d1, q3w
Sponsors
People's Hospital of Jianyang
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with non-small cell lung cancer confirmed by pathology (histology or cytology) (according to WHO classification in 2015); 2. According to the eighth edition of TNM staging, the subjects were patients with stage IIIB non-small cell lung cancer without surgical indications; 3. Patients with measurable tumor focus (spiral CT scan >=10 mm, meeting RECIST 1.1 standard); 4. Patients who had not received systemic chemotherapy before and were unwilling to receive systemic chemotherapy or could not tolerate concurrent chemoradiotherapy for various reasons; 5. Subjects whose functions of important organs meet the following requirements (no blood components and cell growth factors are allowed to be used 2 weeks before the start of the study and treatment) Absolute neutrophil count (ANC) >=1.5x10^9/L; Platelet >=100x10^9/L; Hemoglobin >=9g/dl; Serum albumin >=2.8g/dl; Bilirubin =50 ml/min; Myocardial enzymes Thyroid function was normal. 6. Aged 18 to 75 years old, both male and female; 7. ECoG PS: subjects with 0-1 score; 8. Subjects without contraindications of vascular intervention; 9. Patients with an expected survival time of more than 3 months; 10. Male / female subjects with reproductive potential must agree to receive contraceptive guidance during the study, at least 120 days after the end of treatment; 11. Patients who the researchers believe can benefit from it; 12. The patients were informed and followed up (12) and signed the ICF.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Those who do not conform to the pathological diagnosis of NSCLC; 3. Patients with abnormal coagulation function (INR > 2.0, Pt > 16S) with bleeding tendency or undergoing thrombolytic or anticoagulant therapy are allowed to use low-dose aspirin and low molecular weight heparin prophylactically; 4. The absolute neutrophil count (ANC) was lower than 1500 / mm3; 5. The subjects had severe allergy to paclitaxel or human albumin; 6. The subjects had platinum intolerance; 7. The subjects had serious heart, lung, kidney and liver diseases; 8. Pregnant or lactating women; 9. The patients whose expected survival time was less than 3 months; 10. Subjects who had significant clinical bleeding symptoms or had definite bleeding tendency within 3 months before enrollment; 11. Other patients who were not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse Event;Serious Adverse Event; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;progression-free survival;Disease Control Rate;quality of life;Overall survival; | — |
Countries
China
Contacts
Public ContactWeng Liping
People's Hospital of Jianyang
Outcome results
None listed